These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 17523342

  • 1. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
    Kawai T, Kawakami K, Mikinori K, Takei K, Itoi T, Moriyasu F, Takagi Y, Aoki T, Watanebe K, Matsumoto Y, Rimbara E, Noguchi N, Sasatsu M.
    Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
    [Abstract] [Full Text] [Related]

  • 2. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [Abstract] [Full Text] [Related]

  • 3. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E.
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
    Miwa H, Yamada T, Sato K, Ohta K, Ohkura R, Murai T, Nagahara A, Takei Y, Ogihara T, Sato N.
    Dig Dis Sci; 2000 Jan; 45(1):77-82. PubMed ID: 10695617
    [Abstract] [Full Text] [Related]

  • 5. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T.
    Hepatogastroenterology; 2003 Jan; 50(54):2274-8. PubMed ID: 14696516
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB, Park SJ, Ryu JK, Lee JK, Kim HJ, Bae JS, Jung HS, Park SM.
    Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
    [Abstract] [Full Text] [Related]

  • 7. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
    Shirai N, Furuta T.
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():439-44. PubMed ID: 11979823
    [No Abstract] [Full Text] [Related]

  • 8. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
    Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M.
    Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
    [Abstract] [Full Text] [Related]

  • 9. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
    Shirai N, Furuta T, Sugimoto M, Nakamura A.
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():438-41. PubMed ID: 16363575
    [No Abstract] [Full Text] [Related]

  • 10. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH.
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [Abstract] [Full Text] [Related]

  • 12. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
    Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M.
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
    [Abstract] [Full Text] [Related]

  • 13. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
    Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S, Watanabe S, Sato N.
    Aliment Pharmacol Ther; 1999 Jun; 13(6):741-6. PubMed ID: 10383502
    [Abstract] [Full Text] [Related]

  • 14. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX, Zhao YH, Hao YT.
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
    Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M, Nishikawa K, Ishizuka J, Komatsu Y, Mizushima T, Kagaya H, Hige S, Takeda H, Asaka M.
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
    [Abstract] [Full Text] [Related]

  • 16. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.
    Asaoka D, Nagahara A, Matsuhisa T, Takahashi S, Tokunaga K, Kawai T, Kawakami K, Suzuki H, Suzuki M, Nishizawa T, Kurihara N, Ito M, Sasaki H, Omata F, Mizuno S, Torii A, Ohkusa T, Mine T, Sakaki N.
    Helicobacter; 2013 Dec; 18(6):468-72. PubMed ID: 23773231
    [Abstract] [Full Text] [Related]

  • 17. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
    Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M, Kimoto K, Inokuchi H, Kawai K.
    Aliment Pharmacol Ther; 2003 Jan; 17(2):259-64. PubMed ID: 12534411
    [Abstract] [Full Text] [Related]

  • 18. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G.
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [Abstract] [Full Text] [Related]

  • 19. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M.
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
    [Abstract] [Full Text] [Related]

  • 20. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
    Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.